Syneron Medical Ltd. (ELOS) Shares Down 1.1%
Syneron Medical Ltd. (NASDAQ:ELOS)’s share price dropped 1.1% during mid-day trading on Monday . The stock traded as low as $7.28 and last traded at $7.35, with a volume of 59,630 shares. The stock had previously closed at $7.43.
ELOS has been the topic of several research reports. Zacks Investment Research raised Syneron Medical from a “sell” rating to a “hold” rating in a report on Thursday, June 16th. Brean Capital reissued a “buy” rating on shares of Syneron Medical in a report on Thursday, June 16th.
The company’s market cap is $254.69 million. The stock has a 50-day moving average price of $7.37 and a 200-day moving average price of $7.17.
Syneron Medical (NASDAQ:ELOS) last issued its quarterly earnings data on Thursday, May 19th. The company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of $0.01 by $0.03. The firm earned $68.70 million during the quarter, compared to analyst estimates of $64.38 million. During the same quarter in the prior year, the firm earned $0.02 EPS. The business’s quarterly revenue was up 8.4% compared to the same quarter last year. On average, equities research analysts expect that Syneron Medical Ltd. will post $0.27 EPS for the current year.
Other institutional investors have recently modified their holdings of the company. Lapides Asset Management LLC raised its position in shares of Syneron Medical by 210.4% in the fourth quarter. Lapides Asset Management LLC now owns 237,800 shares of the company’s stock worth $1,833,000 after buying an additional 161,200 shares in the last quarter. Brandes Investment Partners LP raised its position in shares of Syneron Medical by 206.1% in the fourth quarter. Brandes Investment Partners LP now owns 1,745,669 shares of the company’s stock worth $13,459,000 after buying an additional 1,175,299 shares in the last quarter. Finally, Royce & Associates LLC raised its position in shares of Syneron Medical by 7.2% in the fourth quarter. Royce & Associates LLC now owns 663,159 shares of the company’s stock worth $5,113,000 after buying an additional 44,700 shares in the last quarter.
Syneron Medical Ltd. is engaged in manufacture, research, development, marketing and sales of advanced equipment for the aesthetic medical industry and systems for dermatologists, plastic surgeons and other qualified practitioners. The Company designs, develops and markets aesthetic medical products based on its various technologies, including Electro-Optical Synergy (ELOS) technology to provide aesthetic medical treatments.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.